Electromed (ELMD) Investor presentation summary

Company overview and market position

• Focuses on airway management medical devices, headquartered in New Prague, MN, with 174 employees and $54.7M annual revenue as of June 2024.

• Operates in the large, expanding airway clearance market, leveraging HFCWO technology supported by clinical outcomes and strong reimbursement.

• Direct-to-patient distribution model drives attractive gross margins, with most revenue from home care and broad payor coverage.

Product innovation and clinical impact

• SmartVest Clearway is the newest HFCWO device, offering enhanced portability, user interface, and established reimbursement.

• SmartNotes™ provides physicians with patient progress and outcomes, supporting disease management and therapy adherence.

• Clinical studies show SmartVest reduces hospitalizations, antibiotic use, and emergency visits, with high patient satisfaction and improved health outcomes.

Market opportunity and growth strategy

• U.S. bronchiectasis market is underpenetrated, with only ~15% HFCWO penetration and diagnosed population growing at ~12% annually.

• Growth strategy includes sales force expansion, direct-to-consumer marketing, improved diagnosis rates, and expanded e-prescribing.

• Long-term objectives target double-digit revenue growth, increased market share, and operating margin improvement.